Bharat Parenterals Ltd

🔍 Bharat Parenterals' Subsidiary Receives 5 Observations in U.S. FDA Inspection

• U.S. FDA conducted a surprise inspection at Innoxel Lifesciences' Vadodara facility from April 13-17 and April 20, 2026.

• The inspection resulted in 5 observations classified as Voluntary Action Indicated (VAI).

• The company will submit a response to the observations within prescribed timelines.

• The facility has a strong regulatory track record, including a previous U.S. FDA inspection in April-May 2025 and an EU GMP inspection in November 2025, both with zero critical or major observations.